A Closer Look at 4 Analyst Recommendations For Vericel
Portfolio Pulse from Benzinga Insights
In the past three months, Vericel (NASDAQ:VCEL) received four bullish analyst ratings, with two upgrades in the last 30 days. The average 12-month price target is $51.00, marking a 13.03% increase from the previous $45.12. Analysts from Truist Securities and HC Wainwright & Co. have raised their price targets, reflecting optimism about Vericel's market performance and financial health. Vericel, a biopharmaceutical company, has shown solid revenue growth and strong financial metrics, including a notable net margin and ROE.
March 01, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vericel received four bullish ratings recently, with a raised average 12-month price target to $51.00. Analysts from Truist Securities and HC Wainwright & Co. have increased their targets, reflecting a positive outlook on the company's performance.
The unanimous bullish sentiment from analysts, coupled with the recent upgrades in price targets, indicates a strong positive outlook for Vericel. The company's solid revenue growth and financial metrics further support this optimism, suggesting potential short-term upward movement in VCEL's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100